Memantine

Generic Name: Memantine

Brand Names: Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁N

CAS Number: 19982-08-2

Unique Ingredient Identifier: W8O17SJF3T

Background: Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication: Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions: Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Not Applicable

Completed

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Executive Function Deficits (EFD)

Interventions: Drug: Placebo
Drug: Memantine Hydrochloride
Drug: OROS-Methylphenidate

First Posted Date: 2012-02-15

Last Posted Date: 2014-04-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT01533493

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Modafinil
Drug: Donepezil
Drug: Memantine

First Posted Date: 2011-10-27

Last Posted Date: 2015-02-04

Lead Sponsor: Qualissima

Target Recruit Count: 36

Registration Number: NCT01461174

Locations: 🇫🇷
CIC, Lille, France
🇫🇷
MEDES, Toulouse, France

A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease

Phase 2

Completed

Conditions: Huntington Disease

Interventions: Drug: Memantine
Other: Placebo

First Posted Date: 2011-10-24

Last Posted Date: 2020-01-13

Lead Sponsor: University of British Columbia

Target Recruit Count: 19

Registration Number: NCT01458470

Locations: 🇨🇦
The Centre for Huntington Disease, Vancouver, British Columbia, Canada

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma
Supratentorial Glioblastoma

Interventions: Drug: Memantine Hydrochloride
Drug: Mefloquine
Drug: Metformin Hydrochloride
Drug: Temozolomide

First Posted Date: 2011-09-08

Last Posted Date: 2024-07-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 144

Registration Number: NCT01430351

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Alzheimer's Disease - Input of Vitamin D With mEmantine Assay

Phase 3

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Memantine
Drug: Vitamin D placebo
Drug: Vitamin D

First Posted Date: 2011-08-04

Last Posted Date: 2016-09-22

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 90

Registration Number: NCT01409694

Locations: 🇫🇷
University Hospital, Angers, France

Treatment Resistant Geriatric Depression in Primary Care

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Memantine

First Posted Date: 2011-07-12

Last Posted Date: 2017-02-01

Lead Sponsor: Mclean Hospital

Target Recruit Count: 12

Registration Number: NCT01392287

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)

Phase 2

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2011-06-14

Last Posted Date: 2017-03-20

Lead Sponsor: Evdokia Anagnostou

Target Recruit Count: 23

Registration Number: NCT01372449

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

Phase 4

Completed

Conditions: Autism Spectrum Disorders

Interventions: Drug: Memantine

First Posted Date: 2011-04-12

Last Posted Date: 2024-07-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT01333865

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

Phase 2

Completed

Conditions: Subjective Cognitive Impairment
Memory, Concentration or Attention Problems
Retention Disorder, Cognitive
Memory Disorder

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2010-12-16

Last Posted Date: 2013-11-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 299

Registration Number: NCT01261741

Locations: 🇩🇪
Praxis Dr. Heidenreich, Böblingen, Germany
🇩🇪
Praxis Dr. Krause, Wolfratshausen, Germany
🇩🇪
Klinische Forschung Berlin-Mitte, Berlin-Mitte, Germany

and more 11 locations

Memantine for Recurrent Glioblastoma

Phase 2

Terminated

Conditions: Glioblastoma

Interventions: Drug: memantine

First Posted Date: 2010-12-15

Last Posted Date: 2015-12-10

Lead Sponsor: University of Rochester

Target Recruit Count: 4

Registration Number: NCT01260467

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy